First Patient Dosed in Phase II Renal Cancer Theranostics Study
Telix announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s investigational renal cancer therapy at MSK in New York.
ProstACT Update: TARGET Study Ethics Approval
Telix’s ProstACT TARGET Phase II clinical trial of prostate cancer antibody therapy candidate TLX591 has been granted Human Research Ethics Committee approval.
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
Telix announces that the FDA has granted Orphan Drug Designation for TLX66 (90Y-besilesomab), for conditioning treatment prior to hematopoietic stem cell transplant (HSCT).
Telix Advances Development of Glioblastoma Therapy Program
Telix announces significant progress in advancing the Company’s glioblastoma therapy candidate TLX101 into the next stage of clinical development.
EAU Updates Guidance for PSMA-PET Imaging
Telix welcomes the updated 2022 ‘Guidelines on Prostate Cancer’ (the Guidelines) from the European Association of Urology (EAU), which demonstrate an increasing recognition of the clinical utility of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging modalities (PSMA PET), including gallium-68 PSMA-11, in the diagnosis of prostate cancer.
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
Telix announces the ZIRCON Phase III study of investigational kidney cancer imaging agent, TLX250-CDx has dosed the target enrolment of 252 patients.
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
Telix and Kanazawa University announce that the Phase I clinical study of TLX591-CDx for prostate cancer imaging in Japanese patients has met its objectives
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
Telix announces that the first patient has been dosed in the Company’s PSMA-targeting ‘ProstACT’ therapeutic program.
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
Telix is pleased to announce a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective clinical trial investigating the use of O-(2-[18F]fluoroethyl)-L-tyrosine or 18F-FET to image glioblastoma patients with positron emission tomography (PET) (FET-PET). 18F-FET is under development by Telix (referred to as TLX101-CDx) as a complementary diagnostic agent to its TLX101 glioblastoma therapeutic candidate.
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
Telix announces that a first patient has been dosed in the ‘PERTINENCE’ Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer